CJC-1295 + Ipamorelin: The Gold Standard GH Protocol Explained

The combination of CJC-1295 and Ipamorelin is the most widely prescribed GH-axis protocol in physician-supervised longevity medicine. It brings together a long-acting GHRH analogue and a selective ghrelin receptor agonist — two complementary inputs that together exceed what either achieves alone.

By UAE Peptide Clinic Research Desk

The combination of CJC-1295 and Ipamorelin is the most widely prescribed GH-axis protocol in physician-supervised longevity medicine. It brings together a long-acting GHRH analogue and a selective ghrelin receptor agonist — two complementary inputs into the growth hormone axis that together produce a pulse exceeding what either compound achieves alone.

How the Combination Works

CJC-1295 is a GHRH analogue with a drug affinity complex (DAC) modification that extends its half-life significantly, producing a sustained GHRH signal over several days from a single injection. This creates an elevated baseline of GH pulsatility. Ipamorelin adds a clean, cortisol-free ghrelin receptor stimulus on top of this baseline. The two mechanisms are additive: GHRH and ghrelin-receptor signalling converge in the pituitary on different second-messenger pathways, and their combined activation produces larger GH pulses than the sum of their individual effects.

Clinical Outcomes

In physician-supervised protocols running 10 to 12 weeks, the CJC-1295 and Ipamorelin combination is associated with improved body composition, enhanced sleep quality (particularly deep sleep architecture), faster recovery from training, improved skin quality, and better energy. IGF-1 elevates moderately and progressively — typically remaining within physiological range under appropriate dosing.

CJC-1295 and Ipamorelin is where most patients new to GH-axis therapy begin. Our physicians calibrate dose based on your baseline IGF-1 and health goals. Explore the protocol at /peptides/cjc-ipamorelin or take the quiz at /find-my-stack.